Drug-Resistant Gonorrhoea Cases Rise Across Europe
Drug-resistant gonorrhea is spreading in Europe, raising concerns over future treatment options.
"Local transmission of ceftriaxone-resistant gonorrhoea in Europe is a warning sign we should not ignore," says Csaba Ködmön, an ECDC microbiology expert. "While the risk to the general population is currently low, growing resistance reduces the effectiveness of the therapies we rely on today. If highly drug-resistant strains become established and continue to spread, treatment options could become increasingly limited. Strengthening prevention, expanding antimicrobial testing, and promoting timely diagnosis are therefore essential to detect resistant strains early, limit further spread, and keep gonorrhoea treatable."
In a risk assessment published today, ECDC analyses the surge in ceftriaxone-resistant gonorrhoea infections across Europe since 2022 as well as related risks for sexually active people, based on reports from 11 European countries.
According to ECDC’s assessment, the overall risk posed by ceftriaxone-resistant gonorrhoea remains low for the general sexually active population in the European Union and European Economic Area (EU/EEA). It is higher among people having sex without a condom or other means of protection with casual or new partners, people with multiple or frequently changing sexual partners, sex workers and their clients, and for those travelling to areas with a high prevalence of drug-resistant strains of gonorrhoea. Early detections of ceftriaxone-resistant cases in Europe have been associated with importation from areas with higher circulation of such resistant strains, particularly from South-East Asia. This remains the main route of introduction into Europe.
Gonorrhoea is one of the most common bacterial sexually transmitted infections (STI) globally, with an estimated 82 million reported infections each year. There were more than 106 000 confirmed gonorrhoea cases across the EU/EEA in 2024, the highest notification level since the start of EU surveillance in 2009. If left untreated, gonorrhoea infection can lead to severe complications, including pelvic inflammatory disease, infertility and ectopic pregnancy.
Prevention of gonorrhoea infection remains straightforward with correct and consistent use of condoms or other barrier methods when having sex, getting tested regularly especially after sex with new, casual or multiple sexual partners, and seeking testing after possible exposure.
ECDC makes several recommendations for public health authorities and healthcare providers to address the risk and maintain the effectiveness of current gonorrhoea treatments, including:
- continued surveillance of gonococcal antimicrobial resistance;
- antimicrobial susceptibility testing;
- effective clinical management; and
- targeted prevention measures to limit spread, including clear messages on safer sex, regular testing for those with new or casual partners, and timely treatment if symptoms appear or there has been potential exposure.
Reference: Upsurge in ceftriaxone-resistant Neisseria gonorrhoeae with evidence of domestic transmission in the EU/EEA and the UK. Published 2026. https://www.ecdc.europa.eu/en/publications-data/upsurge-ceftriaxone-resistant-neisseria-gonorrhoeae-evidence-domestic Accessed July 20, 2026.
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
